Learn From The Psychiatry Experts: Schizophrenia and Long-Acting Injectables (LAIs) Webinar Series
In this webinar series, psychiatry experts discuss the neurobiology and predictors of schizophrenia relapse, and the potential role for long-acting injectables (LAIs) in the management of schizophrenia. The published evidence comparing the features and patient outcomes of LAIs vs. oral antipsychotics is explored, in addition to practical tips for navigating barriers and implementing LAIs in your practice. These topics are further complemented with the use of real-world patient cases.
Schizophrenia Relapse: Prevention, Predictors, and Potential Mechanisms
- Importance of preventing relapse in schizophrenia
- Predictors of relapse in schizophrenia ㅤ
ㅤ- Following antipsychotic discontinuation ㅤ
ㅤ- Despite ongoing antipsychotic treatment
- Neurobiology of psychosis relapse
ㅤ- Following antipsychotic discontinuation
ㅤ- Despite ongoing antipsychotic treatment
(Video length: 17 minutes, subtitles available)
Real-World Outcomes of Long-Acting Injectable Antipsychotic Agents
- Mechanisms of action in schizophrenia
- Long-acting antipsychotic agents versus oral antipsychotic agents(formulations, efficacy and safety, discontinuation rates, quality of life,morbidity and mortality
- Implementing long-acting antipsychotic agents
- Real-world examples of long-acting antipsychotic agent use
(Video length: 18 minutes, subtitles available)
Navigating Real-World Barriers to the Utilization of Long-Acting Injectable Antipsychotic Agents
- Barriers to long-acting antipsychotic agent use
- Potential solutions to increase long-acting antipsychotic agent use
- Real-world examples of overcoming barriers to long-acting antipsychoticagent use
(Video length: 18 minutes, subtitles available)